Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tongning Gel is a topical Traditional Chinese Medicine (TCM) formulation developed by Jiangsu Kanion Pharmaceutical for the treatment of knee osteoarthritis. It is designed to provide localized analgesic and anti-inflammatory effects directly at the site of joint pain. The gel formulation facilitates the delivery of active herbal constituents, which typically include extracts from *Corydalis yanhusuo*, *Olibanum* (Frankincense), and *Myrrha* (Myrrh). These components are traditionally used to improve blood circulation, resolve blood stasis, and alleviate pain associated with degenerative joint diseases. Tongning Gel has undergone Phase 3 clinical trials in China to evaluate its efficacy in reducing pain and improving physical function in patients with knee osteoarthritis, positioning it as a non-systemic therapeutic option for chronic joint pain management.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Tongning Gel.